07 Oct Therapeutic Benefits of CBD Oils in Massage Therapy: A Clinical Perspective
Posted at 11:30h
in Cannabis
[caption id="attachment_63791" align="aligncenter" width="500"] Photo from Freepik[/caption]
The search for natural pain relief and wellness solutions has led many to rediscover the therapeutic power of CBD. When combined with massage therapy, CBD oils may offer a powerful synergy, potentially promoting relaxation, reducing inflammation, and alleviating chronic discomfort. This blend of science-backed benefits and holistic care transforms a simple massage into a deeply rejuvenating experience. As more people seek non-invasive alternatives for their health, CBD-infused massage therapy may help provide an effective option for mind and body healing.
Amy Kennalley[/caption]
Amy Kennalley, MBS
First Year Medical Student
Department of Medical Education
Geisinger Commonwealth School of Medicine
MedicalResearch.com: What is the background for this study
Response: The legalization of medical marijuana (MMJ) and the number of qualifying conditions are expanding across the USA, emphasizing the need to understand the implications of MMJ dispensary distribution for equitable access. Pennsylvania (PA) legalized MMJ in 2016, with the first dispensary opening its doors in 2018. The state currently recognizes 24 medical conditions for MMJ use, including six for which there is insufficient or no evidence for their efficacy as a treatment. Prior research suggests that there is a link between proximity to dispensaries and overall MMJ use. However, a gap exists in our understanding of how dispensary locations might be associated with the specific qualifying conditions for which individuals receive their certification.
In response to this knowledge gap, our study delved into the medical marijuana dispensary access in PA and explored associations with both MMJ certifications and the community demographics. Utilizing data from the Pennsylvania Department of Health, we investigated how proximity to MMJ dispensaries related to the proportion of individuals certified for MMJ use within a specific area or Zip Code Tabulation Area. Additionally, we analyzed the proportion of certifications for conditions with varying levels of evidence supporting the efficacy of MMJ.
This pioneering study represents the first of its kind in PA, shedding light on the association between MMJ dispensary locations and certifications. Likewise, it is the first in the US to investigate the link between dispensary locations and specific qualifying conditions. By examining these dynamics, we aim to contribute vital insights to inform policy and practice, ensuring equitable access to MMJ treatment for individuals with diverse medical needs.
Dr. Di Ciano[/caption]
Patricia Di Ciano, PhD
Luke Cavanah[/caption]
Luke Cavanah, BS
Geisinger Commonwealth School of Medicine
Scranton, PA
MedicalResearch.com: What is the background for this study?
Response: It is well-known that schedule II stimulants, which are those that are highly addictive and include amphetamine, methylphenidate, and lisdexamfetamine, have had increasing use and misuse in the US.
Despite understanding the presence of this phenomenon, the reason for it is poorly understood. The purpose of this study was to see if rising rates of schedule II stimulants are related to the legalization of medical marijuana. We were interested in this because schedule II stimulants are primarily used as the treatment for attention-deficit hyperactivity disorder (ADHD), chronic cannabis use has been demonstrated to cause neurocognitive deficits resembling that of ADHD, and the conditions have been shown to affect similar brain regions.
Dr. Kruger[/caption]
Jessica Kruger PhD
Clinical Associate Professor of Community Health and Health Behavior
University at Buffalo School of Public Health and Health Professions
MedicalResearch.com: What is the background for this study?
Response: The 2018 Farm Bill authorizing hemp production led to new cannabinoids in the consumer marketplace. As the market becomes increasingly saturated with suppliers, companies continually diversify available products.
The rapid emergence of novel cannabinoids outpaces systematic research necessary to inform regulations and harm reduction. Empirical evidence is needed to guide policies, practices, and education of consumers. Product manufacturers, social media participants, and cannabis oriented on-line news sources have claimed that THC-O-acetate is a "psychedelic" cannabinoid, producing experiences similar to those associated with LSD, psilocybin, mescaline, and DMT.
Dr. Potnuru[/caption]
Paul Potnuru, MD
Assistant Professor
Anesthesiology, Critical Care and Pain Medicine
The John P. and Kathrine G. McGovern Medical School
The University of Texas Health Science Center at Houston
Dr. Miller[/caption]
Alex P. Miller, PhD
TranSTAR T32 Postdoctoral Fellow
Department of Psychiatry
Washington University School of Medicine
St. Louis, MO
MedicalResearch.com: What is the background for this study?
Response: Adolescent cannabis use is increasing in the United States. Prior research suggests that people who start using cannabis earlier are more likely to engage in problematic use and also experience greater mental health challenges and socioeconomic disadvantages overall. For example, children who begin using cannabis early are more likely to have behavioral problems and disorders and are more less likely to complete school.
In our study, we used data from the Adolescent Brain Cognitive Development (ABCD) Study, which is following nearly 12,000 kids across the nation to track behavior and brain development as well as health from middle childhood to young adulthood. We looked at what factors are associated with the initiation of cannabis use by age 12-14.
Dr. Lovestead[/caption]
Tara M Lovestead, PhD, (She/her/hers)
Dr. Lazarus[/caption]
Philip Lazarus, PhD
Boeing Distinguished Professor, Pharmaceutical Sciences
Professor, Dept of Pharmaceutical Sciences
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, WA 99210
MedicalResearch.com: What is the background for this study?
Response: Smoking and tobacco use remains a major health issue. Smokers use cigarette over the course of the day because the levels of nicotine, the addictive agent in cigarettes and other forms of tobacco, dimmish with time in the bloodstream due to the breakdown of nicotine by enzymes in the body. By inhibiting the breakdown of nicotine in smokers, one would expect that the levels of nicotine would remain higher after smoking a single cigarette, and that these individuals may not require lighting up another cigarette so quickly, reducing the number of cigarettes smoked over the course of a day. This could have a profound effect on reducing the overall harm incurred from smoking or from using other forms of tobacco.
In a single previous study, smokers who used a CBD inhaler exhibited a 40% reduction in cigarette use. In addition, while cannabis users are often smokers, previous studies have indicated that they smoke less cigarettes than non-cannabis-using cigarette smokers. In previous studies published in 2021, we found that major cannabinoids present in cannabis like THC and CBD inhibit major metabolizing enzymes in our body, including several that are important in drug metabolism. We hypothesized that CBD and its major active metabolite, 7-hydroxy (OH)-CBD, may also be inhibiting one or more of the enzymes important in the metabolism (or breakdown) of nicotine.
Dr. Wong[/caption]
Mitchell Wong, MD PhD
Professor of Medicine
Executive Vice Chair for Research Training
Department of Medicine
Executive Co-Director, Specialty Training and Advanced Research (STAR) Program
Director, UCLA CTSI KL2 Program
UCLA Division of General Internal Medicine and Health Services Research Los Angeles, CA 90024
MedicalResearch.com: What is the background for this study?
Response: It is estimated that social factors like poverty, education, and housing have a large impact on health. Yet, there are few interventions that exist to directly address those issues. Schools are a promising solution since society already invests heavily in education and schools are an everyday part of most children’s lives.
Dr. Myran[/caption]
Daniel Myran, MD, MPH, CCFP, FRCPC
Family and Public Health and Preventive Medicine Physician
CIHR Fellow, Ottawa Hospital Research Institute
Department of Family Medicine Innovation Fellow
University of Ottawa
MedicalResearch.com: What is the background for this study?
Response: Canada legalized recreational, or non-medical, cannabis in October 2018. Canada took phased approach to legalization initially only allowing flower-based cannabis products and oils and after one year permitting the sale of commercial cannabis edibles (e.g. THC containing candies, baked goods, and drinks). In this study we took advantage of this phased roll out of legal cannabis to understand the impact of legalization on cannabis exposures or poisonings in children aged 0-9 years and the contribution of different types of cannabis products to these events.
